MEDPMEDPHealthcare · Diagnostics & Research

MEDP Stock Forecast: Medpace Holdings, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$610
−3.71% on the day

The 14 Wall Street analysts covering Medpace Holdings, Inc. hold a median 12-month price target of $675 — +10.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 93 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$17.1B
Ticker Nerd rank
93/ 100
Median analyst target
$675
Analysts covering
14
Revenue$707.3M+17.2% y/y
Operating income$146.8M
Net income$121.4M
Free cash flow$138.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.7%
1M
−1.9%
YTD
+8.7%
1Y
+4.1%
From 52W high
−11.9%
From 52W low
+55.2%
$393
$693
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Medpace Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
93/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
97
Revisions
91
Volatility
80
Momentum
79
Growth
72
Issuance
67
Value
67
Accruals
63

Quality (97): The business earns solid, repeatable profits on what it owns.

Accruals (63): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MEDP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MEDP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$300$400$500$600$700$800Jan 26Apr 26Jul 26Oct 26MEDPHigh $730Median $675Low $370

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
2
Buy
11
Hold
1
Sell
$370
Low
$675
Median
$730
High

The green dot is the last close — the median target sits +10.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 17 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
26 Oct 2026BMO CapitalMaintainsMarket Perform$600 → $670
23 Oct 2026BarclaysMaintainsEqual-Weight$625 → $675
23 Oct 2026TD CowenMaintainsHold$492 → $673
23 Oct 2026Truist SecuritiesMaintainsHold$609 → $633
23 Oct 2026UBSMaintainsNeutral$673 → $700
7 Oct 2026BarclaysMaintainsEqual-Weight$600 → $625
7 Oct 2026MizuhoMaintainsOutperform$665 → $700
30 Sept 2026UBSUpgradeNeutral$405 → $673
24 July 2026BairdMaintainsNeutral$547 → $624
24 July 2026BMO CapitalMaintainsMarket Perform$400 → $600
24 July 2026MizuhoMaintainsOutperform$586 → $665
24 July 2026RBC CapitalMaintainsOutperform$484 → $692
24 July 2026TD CowenMaintainsHold$419 → $492
24 July 2026Truist SecuritiesMaintainsHold$462 → $609
13 July 2026MizuhoMaintainsOutperform$495 → $586
8 July 2026BairdDowngradeNeutral$477 → $547
7 July 2026JefferiesDowngradeHold$490 → $515
24 Apr 2026BairdMaintainsOutperform—
24 Apr 2026BarclaysMaintainsEqual-Weight—
24 Apr 2026BMO CapitalMaintainsMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MEDP.

Market Radar

This page is one stock. Monday covers all of them.

MEDP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MEDP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Medpace Holdings, Inc. returned +4.1% against +6.9% for the S&P 500, dividends included.

MEDP vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26MEDPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MEDP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+3.7%
Analysts raising
10
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
33.9×

Cheaper than 25% of US stocks

Price / sales
6.0×

Cheaper than 18% of US stocks

Price / book
29.2×

Cheaper than 2% of US stocks

EV / EBITDA
26.1×

Cheaper than 14% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
23.7%

Higher than 62% of US stocks

Gross margin
28.5%

Higher than 32% of US stocks

Operating margin
21.4%

Higher than 81% of US stocks

Net margin
18.2%

Higher than 79% of US stocks

Returns & dividend
Return on equity
117.9%

Higher than 97% of US stocks

Return on assets
18.7%

Higher than 98% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Medpace Holdings, Inc. has a market value of $17.1B and an enterprise value of $16.5B.

  • Revenue in the twelve months to 30 June 2026: $2.8B. The latest quarter grew 17.2% year on year.

  • Net income over the same four quarters: $491.5M, a 17.7% net margin.

  • Diluted earnings per share, trailing twelve months: $17.06.

  • Free cash flow in the twelve months to 30 June 2026: $706.7M.

  • Medpace Holdings, Inc. spent $299.3M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 27.9M.

  • Trailing P/E: 33.9×; forward P/E: 30.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Medpace Holdings, Inc. employs 6,600 people — $422K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

MEDP and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
MEDPMedpace Holdings, Inc.$17.1B93
RVTYRevvity, Inc.$16.2B97
GHGuardant Health, Inc.$18.9B46
CRLCharles River Laboratories International, Inc.$15.5B87
ICLRICON plc$14.3B75
DGXQuest Diagnostics, Inc.$28.7B93
ILMNIllumina, Inc.$29.1B95

Take a look at MEDP’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Medpace Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MEDP

What is the MEDP stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Medpace Holdings, Inc. have a median 12-month price target of $675, with estimates ranging from $370 to $730. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MEDP stock a buy right now?

Of the 14 analysts covering Medpace Holdings, Inc., 2 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Medpace Holdings, Inc. 93 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MEDP?

As at 21 Nov 2026, Medpace Holdings, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).

Will MEDP stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +10.6% from the last close, and Ticker Nerd's factor model ranks Medpace Holdings, Inc. 93 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MEDP stock forecast for 2030?

No analyst covering Medpace Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MEDP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $370 to $730 over the next 12 months.

How has MEDP stock performed over the past year?

Medpace Holdings, Inc. returned +4.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Medpace Holdings, Inc. do?

Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support.

Company

About Medpace Holdings, Inc.

Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support. The company also offers specialized laboratory and trial support capabilities such as central laboratory services, bioanalytical testing, imaging core laboratory services, and cardiac safety assessments. Medpace serves clients across North America, Europe, Asia, South America, Africa, and Australia, playing a central role in helping sponsors run complex clinical programs and advance medical products through development.

CEO Dr. August James Troendle M.D. · 6,600 employees · United States · https://www.medpace.com